Symptoms and General Pathology

All Conditions

Neoplasms

Nervous System Diseases

Diseases and Abnormalities at or Before Birth

Rare Diseases

Sclerosis

Neoplasm Metastasis

Tuberous Sclerosis

Neoplastic Processes

Tuberous Sclerosis Complex

Anti-Infective Agents

Antineoplastic Agents

All Drugs and Chemicals

Sirolimus

Temsirolimus

MTOR Inhibitors

Anti-Bacterial Agents

Antibiotics, Antitubercular

Clotrimazole

Miconazole

Antifungal Agents

Immunosuppressive Agents

Immunologic Factors

Patients with pathogenic inactivating TSC1 alterations.

Patients with pathogenic inactivating TSC2 alterations.

Prospective phase 2, open-label, multi-institutional basket trial to determine the efficacy and safety of nab-sirolimus administered by IV infusion to patients

nab-sirolimus

Aadi Bioscience Medical Information

Tempus

Karla Childers

Sherri Arledge, MD

Erika Arguello Vargas

Allan Espinosa Morazan, MD

Terry Thomas

Lyndsay Willmott, MD

Erika Aruello

Alphea Bonds Castro

David Palchak, MD

Kumar Sankhala, MD

Nazeli Livaskani

Jacob Thomas, MD

Nazanin Kavenhfar

Noah Federman, MD

Jericho Rabago

Michael Demeure, MD

Victoria Chua

Erlinda Maria Gordon, MD

Camille Shaffer

Ian Anderson, MD

Khadija Bedar

Kristen Ganjoo, MD

Omkar Marathe, MD

Jennifer Hege

Patrick Eulitt, MD

Staci Williams

Maen Hussein, MD

Patel Chandni

Magali Van den Bergh, MD

Chandni Patel

Barry S Berman, MD

Chandri Park

Justin Elkins

Gaurav Trikha, MD

Robert Doran

Shanna Kennedy

Kamal Sharma, DO

Chandni Park

Praneetha Achanta

Srilata Gundala, MD

Sunil Babu, MD

Chelsea Formato

Ebenezer Kio, MD

Jenelle Larkin

Mark Goldstein, MD

Ava Greenberg

Candace Haddox, MD

Ola Atchison

Dipesh Uprety, MD

Jinan Ali

Sushma Tatineni

Allie Gordon

Brian A Van Tine, MD

Lauren Murphy

David Crockett, MD

Teresa Ryba

Brent Tierney, MD

Audrey Ades

Jill Morrison, MD

A Phase 2 multi-center open-label basket trial of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes

Study TSC-007 is a prospective phase 2, open-label, multi-institutional basket trial to determine the efficacy and safety profile of nab-sirolimus administered to patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes. Patients will be treated with single agent IV nab-sirolimus until disease progression, or unacceptable toxicity, or until in the opinion of the investigator the patient is no longer benefiting from therapy, or at patient discretion.

Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)

A Phase 2 Multi-center Open-label Basket Trial of Nab-sirolimus for Adult and Adolescent Patients With Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 or TSC2 Genes.

ORR based on the proportion of patients with best overall response (BOR) of confirmed partial response (PR) or complete response (CR) from the time of study treatment initiation until disease progression as determined by IRR using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1

Determined for patients with BOR of confirmed CR or PR (by IRR)

BOR of confirmed CR or PR (either of any duration) or stable disease (SD) following study treatment initiation (by IRR)

Time from first dose of study drug to initial measurement of CR or PR, where CR or PR is subsequently confirmed

Number of months from study treatment initiation to the date of disease progression (by IRR) or death due to any cause

Number of months from study treatment initiation to the date of death due to any cause

Changes from baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire v3.0 (EORTC-QOQ-C30) scores

Incidence and severity of treatment-emergent and treatment-related AEs as assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0

Aadi Bioscience, Inc.

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Recurrence

Carcinoma

Endometrial Neoplasms

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Disease Attributes

Uterine Neoplasms

Genital Neoplasms, Female

Urogenital Neoplasms

Uterine Diseases

Genital Diseases, Female

Genital Diseases

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Letrozole

Patients with advanced or recurrent endometrioid endometrial carcinoma

Prospective Phase 2, open-label, multi-institutional study to evaluate the efficacy and safety of nab-sirolimus + letrozole in patients

Aaron Holley

Matthew Kovak

Michelle McClosky

Brian Slomovitz, MD

Thania Escamilla

Jacky Amador

Nicola M Spirtos, MD

Angela Green, MD

Leah J Wilson, BS, RN, OCN

Allison M Puechi, MD

Christine Pappaterra

Lauren Dockery, MD

Pamela Smith

Cara Mathews, MD

Shelly Maxfield, CCRP

Anna Priebe, MD

Anh Lam

Fernanda Musa, MD

Willis Navarro, MD

A Phase 2 Multi-center Open-label Trial of nab-Sirolimus in Combination with Letrozole in Advanced or Recurrent Endometrioid Endometrial Cancer

This is a prospective phase 2, open-label, multi-institutional study to evaluate the efficacy and safety of nab-sirolimus + letrozole in patients with advanced or recurrent endometrioid endometrial carcinoma who have received 0-1 prior lines of chemotherapy in the recurrent/metastatic setting. Patients will be treated with nab-sirolimus (given IV on Days 1 and 8 in a 21-day cycle, combined with letrozole (orally, daily) until unacceptable toxicity or disease progression, or until in the opinion of the Investigator the patient is no longer benefiting from therapy, or at patient discretion.

Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer

A Phase 2 Multi-center Open-label Trial of Nab-Sirolimus in Combination With Letrozole in Advanced or Recurrent Endometrioid Endometrial Cancer

ORR, defined as the proportion of patients with best overall response (BOR) of confirmed partial response (PR) or complete response (CR) from the time of study treatment initiation until progression of disease (PD) as determined by the Investigator using RECIST v1.1.

Determined for patients with BOR of confirmed CR or PR

Time from study treatment initiation to initial measurement of CR or PR, where CR or PR is subsequently confirmed

Number of months from study treatment initiation to the date of disease progression 3 or death due to any cause

Number of months from study treatment initiation to the date of death due to any cause or last follow up date if alive

Of treatment-emergent and treatment-related adverse events as assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE)

Digestive System Diseases

Gland and Hormone Related Diseases

Neuroendocrine Tumors

Adenoma

Adenoma, Islet Cell

Intestinal Neoplasms

Pancreatic Neoplasms

Stomach Neoplasms

Neuroectodermal Tumors

Neuroectodermal Tumors, Primitive

Neoplasms, Germ Cell and Embryonal

Neoplasms, Nerve Tissue

Gastrointestinal Neoplasms

Digestive System Neoplasms

Endocrine Gland Neoplasms

Gastrointestinal Diseases

Pancreatic Diseases

Endocrine System Diseases

Intestinal Diseases

Stomach Diseases

Neuroendocrine Tumor

Gastro-enteropancreatic Neuroendocrine Tumor

Pancreatic Neuroendocrine Tumor

Pancreatic Cancer

Stomach Cancer

Neuroepithelioma

Gastrointestinal Agents

Pancrelipase

Pancreatin

Patients with well-differentiated neuroendocrine tumors of the gastrointestinal tract, lung, or pancreas.

Prospective phase 2 single arm, open-label, multi-institutional study to determine the efficacy and safety prospective of nab-sirolimus administered by IV infusion

Jason Ledesma

Jennifer Hedge

Allen Cohn, MD

Christine Terraciano

Scott Paulson, MD

Alexandria Phan, MD

A Phase 2 multi-center, open-label, single arm study of nab-sirolimus in patients with well-differentiated neuroendocrine tumors (NETs) of the gastrointestinal tract, lung, or pancreas who have not received prior treatment with mTOR inhibitors

This is a prospective phase 2 single arm, open-label, multi-institutional study to determine the efficacy and safety prospective of nab-sirolimus and patients with functional or non-functional, well-differentiated, locally advanced unresectable in metastatic NETs of the GI tract, lung, or pancreas.

Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors

A Phase 2 Multi-center, Open-label, Single Arm Study of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors

Objective Response Rate (ORR), defined as the proportion of patients with best overall response (BOR) of confirmed partial response (PR) or complete response (CR) from the time of study treatment initiation until progression of disease (PD) as determined by the Investigator using RECIST v1.1

Incidence and severity of treatment-emergent and treatment-related adverse events (AEs) as assessed by NCI CTCAE v5.0

Determined for patients with BOR of confirmed CR or PR defined as time from scan first showing response by RECIST v1.1 to PD or death

BOR of confirmed CR or PR (either of any duration) or stable disease (SD) ≥12 weeks by RECISTv1.1 following study treatment initiation

Time from first dose of study medication to initial measurement of CR or PR, where CR or PR is subsequently confirmed by RECIST v1.1

Number of months from study treatment initiation to the date of disease progression or death due to any cause

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)	NCT05103358	Tumor Tumor, Solid Metastasis Metastatic Canc... Cancer Cancer Metastat... Tumors Neoplasms Neoplasm Metast... Solid Tumor Advanced Solid ... Advanced Cancer Malignant Solid... Malignant Solid... Malignant Neopl... Malignant Tumor TSC TSC1 TSC2 Metastatic Soli... Metastatic Neop...	nab-sirolimus	12 Years -	Aadi Bioscience, Inc.
Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)	NCT05103358	Tumor Tumor, Solid Metastasis Metastatic Canc... Cancer Cancer Metastat... Tumors Neoplasms Neoplasm Metast... Solid Tumor Advanced Solid ... Advanced Cancer Malignant Solid... Malignant Solid... Malignant Neopl... Malignant Tumor TSC TSC1 TSC2 Metastatic Soli... Metastatic Neop...	nab-sirolimus	12 Years -	Aadi Bioscience, Inc.
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer	NCT05997017	Endometrial Can... Endometrioid Tu... Cancer Tumor Recurrent Endom... Endometrioid En...	nab-sirolimus	18 Years -	Aadi Bioscience, Inc.
Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors	NCT05997056	Neuroendocrine ... NET Pancreatic Neur... Gastrointestina... Pulmonary Neuro...	nab-sirolimus	18 Years -	Aadi Bioscience, Inc.

Spots Global Cancer Trial Database for fyarro

Every month we try and update this database with for fyarro cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for fyarro

Every month we try and update this database with for fyarro cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for fyarro cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.